Jounce Therapeutics, Inc. Common Stock
JNCE
JNCE was delisted on the 3rd of May, 2023.
102 hedge funds and large institutions have $207M invested in Jounce Therapeutics, Inc. Common Stock in 2020 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 21 increasing their positions, 40 reducing their positions, and 12 closing their positions.
100% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 12
15% more capital invested
Capital invested by funds: $180M → $207M (+$27.5M)
13% more funds holding
Funds holding: 90 → 102 (+12)
12% more call options, than puts
Call options by funds: $1.72M | Put options by funds: $1.54M
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
48% less repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 40
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
+$5.76M |
| 2 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$2.19M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$641K |
| 4 |
HSA
Hussman Strategic Advisors
Ellicott City,
Maryland
|
+$632K |
| 5 |
Verition Fund Management
Greenwich,
Connecticut
|
+$561K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$2.58M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.49M |
| 3 |
AQR Capital Management
Greenwich,
Connecticut
|
-$1.56M |
| 4 |
Renaissance Technologies
New York
|
-$1.22M |
| 5 |
OFM
Omega Fund Management
Boston,
Massachusetts
|
-$1.21M |
JNCE Hedge Fund Activity: Q3 2020 in Review
102 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Jounce Therapeutics, Inc. Common Stock (JNCE) for Q3 2020, worth a combined $207M — up 15% from $180M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new JNCE positions and 12 closed out — a net gain of 12 holders — while 21 added to existing stakes and 40 trimmed.
The largest buyer was Woodline Partners, opening a new position worth an estimated $5.76M. The largest seller was Citadel Advisors, cutting an estimated $2.58M.
- 102 institutional investors held Jounce Therapeutics, Inc. Common Stock (JNCE) as of Q3 2020, up from 90 in Q2 2020.
- Funds reported $207M of Jounce Therapeutics, Inc. Common Stock stock for Q3 2020, up 15% quarter-over-quarter.
- 24 funds opened new Jounce Therapeutics, Inc. Common Stock positions in Q3 2020 and 12 closed out, a net change of +12 holders.
- The largest Jounce Therapeutics, Inc. Common Stock buyer in Q3 2020 was Woodline Partners, an estimated $5.76M added.
- The largest Jounce Therapeutics, Inc. Common Stock seller in Q3 2020 was Citadel Advisors, an estimated $2.58M sold.
Based on aggregated 13F filings for Q3 2020.